After canceling plans to go public in an initial public offering, image-guided radiotherapy developer ViewRay accomplished the feat anyway with a reverse merger.
The firm's stock is trading on the OTC Markets under the symbol VRAY.
Concurrent with going public, ViewRay announced that it had raised $26.7 million in a private placement of more than 5 million sales of its common stock. The proceeds will be used for the commercialization of the company's MRIdian MRI-guided radiation therapy system, as well as for research and development and general corporate purposes, according to the firm.
